A clearstate report

Next-generation sequencing (NGS) in cancer biomarker testing

The global cancer burden is increasing, with more patients undergoing biomarker testing in order to access more targeted and effective therapies. Economist Intelligence Clearstate expects the number of patients undergoing routine molecular testing for cancer biomarkers tracked by IVD Gateway to grow at an average annual rate between 6.2 to 19.2% in EU5 countries from 2020 to 2025. In Latin America it will grow between 4.1 to 13.1% from 2020 to 2025, to as high as more than 30% average annual growth from 2021 to 2026 in the Asia-Pacific (APAC)’s fastest-growing market for the segment.

While PCR-based molecular diagnostics (MDx) is an essential component of cancer care, molecular testing technologies such as next-generation sequencing (NGS) that supports rapid, high-throughput, highly sensitive, affordable testing, are becoming of increasing importance as the burden of cancer rises. 

This paper explores the state of NGS testing for cancer biomarkers.